<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691455</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-1053</org_study_id>
    <nct_id>NCT02691455</nct_id>
  </id_info>
  <brief_title>The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)</brief_title>
  <acronym>ASSISTS</acronym>
  <official_title>The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Feldman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outcomes of subjects with uncontrolled glaucoma with a single existing aqueous tube shunt&#xD;
      implant undergoing a second aqueous shunt to transscleral diode laser cyclophotocoagulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study comparing short- (1 year), mid- (3 years), and long-term (5 years) cumulative&#xD;
      incidences of failures in participants who undergo a second aqueous shunt (SAS) to those&#xD;
      cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS) to&#xD;
      those cumulative incidences of failures in participants who undergo transscleral diode laser&#xD;
      cyclophotocoagulation (TLC) for eyes with uncontrolled glaucoma with a single existing&#xD;
      aqueous tube shunt procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruiting participants&#xD;
  </why_stopped>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eyes That Failed Treatment</measure>
    <time_frame>from time of intervention to month 6</time_frame>
    <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Eyes That Failed Treatment</measure>
    <time_frame>from month 6 to month 12</time_frame>
    <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Eyes That Failed Treatment</measure>
    <time_frame>from month 12 to year 3</time_frame>
    <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Vision-threatening Complications</measure>
    <time_frame>from the time of intervention to year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes That Lost Two or More Lines of Vision as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>from time of intervention to year 3</time_frame>
    <description>The Snellen visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). Loss of lines of vision indicates worsening visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, week 1</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The week 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, month 1</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, month 3</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 6 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, month 12</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 12 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, year 2</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 2 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</measure>
    <time_frame>baseline, year 3</time_frame>
    <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pain</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants who reported pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pain</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants who reported pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Pain</measure>
    <time_frame>1 week</time_frame>
    <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Pain</measure>
    <time_frame>1 month</time_frame>
    <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Office Visits Per Participant From Baseline to 3 Months</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Office Visits Per Participant Per Month After Month 3</measure>
    <time_frame>from month 4 to year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute (NEI) Visual Function Questionnaire (VFQ) 25 (NEI-VFQ-25) - General Health Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute (NEI) Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Health Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</measure>
    <time_frame>baseline</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</measure>
    <time_frame>month 12</time_frame>
    <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transscleral Cyclophotocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transscleral Diode Laser Cyclophotocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt Glaucoma Implant 350-mm2 / BG101-350</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transscleral Diode Laser Cyclophotocoagulation</intervention_name>
    <description>Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
    <arm_group_label>Transscleral Cyclophotocoagulation</arm_group_label>
    <other_name>Transscleral Diode Laser Cyclophotocoagulation (TLC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed Model FP7 Flexible Plate</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt Glaucoma Implant 250-mm2 / BG103-250</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women and men 18 to 85 years of age&#xD;
&#xD;
          -  Glaucoma not adequately controlled (IOP &gt;18 mmHg on maximum tolerated topical therapy)&#xD;
             with a single aqueous shunt (AS).&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) of hand motion (HM) or better in the study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Monocular&#xD;
&#xD;
          -  Presence of more than one AS in the study eye&#xD;
&#xD;
          -  Previous cyclodestruction in the study eye&#xD;
&#xD;
          -  Presence of active iris neovascularization in the study eye&#xD;
&#xD;
          -  Binocular diplopia&#xD;
&#xD;
          -  Presence of scleral buckle in the study eye&#xD;
&#xD;
          -  History or scleritis in either eye&#xD;
&#xD;
          -  History of scleromalacia in the study eye&#xD;
&#xD;
          -  Insufficient conjunctiva to cover AS in the study eye&#xD;
&#xD;
          -  IOP cannot be accurately measured with Goldmann applanation, Pneumotonometry, or&#xD;
             Tono-Pen in the study eye&#xD;
&#xD;
          -  Presence of silicone oil in the study eye&#xD;
&#xD;
          -  Presence of retinal detachment in the study eye&#xD;
&#xD;
          -  Presence of intraocular or orbital tumor affecting the study eye&#xD;
&#xD;
          -  Need for cataract extraction or concurrent procedure at the time of study treatment,&#xD;
             except tectonic aqueous shunt revisions for both groups is allowed.&#xD;
&#xD;
          -  In the opinion of the investigator, should not be enrolled in this study&#xD;
&#xD;
          -  Unwilling or unable to give consent and satisfy requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Feldman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert Cizik Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego - Shiley Eye Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence and Glaucoma Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Eye Center - Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Consultants of St. Louis</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers; New Jersey Medical School; IOVS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Institute of Northern NJ, LLC</name>
      <address>
        <city>Rochelle Park</city>
        <state>New Jersey</state>
        <zip>07062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Harkness Eye Institute / Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Kittner Eye Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devers Eye Institute/Legacy Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Eye Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Cizik Eye Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine Eye Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WVU Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <reference>
    <citation>Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012. Ophthalmology. 2015 Aug;122(8):1615-24. doi: 10.1016/j.ophtha.2015.04.015. Epub 2015 Jun 16.</citation>
    <PMID>26092196</PMID>
  </reference>
  <reference>
    <citation>Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012 May;153(5):789-803.e2. doi: 10.1016/j.ajo.2011.10.026. Epub 2012 Jan 15.</citation>
    <PMID>22245458</PMID>
  </reference>
  <reference>
    <citation>Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015 Feb;122(2):308-16. doi: 10.1016/j.ophtha.2014.08.043. Epub 2014 Oct 17.</citation>
    <PMID>25439606</PMID>
  </reference>
  <reference>
    <citation>Anand A, Tello C, Sidoti PA, Ritch R, Liebmann JM. Sequential glaucoma implants in refractory glaucoma. Am J Ophthalmol. 2010 Jan;149(1):95-101. doi: 10.1016/j.ajo.2009.07.019. Epub 2009 Oct 17.</citation>
    <PMID>19837382</PMID>
  </reference>
  <reference>
    <citation>Burgoyne JK, WuDunn D, Lakhani V, Cantor LB. Outcomes of sequential tube shunts in complicated glaucoma. Ophthalmology. 2000 Feb;107(2):309-14.</citation>
    <PMID>10690831</PMID>
  </reference>
  <reference>
    <citation>Ness PJ, Khaimi MA, Feldman RM, Tabet R, Sarkisian SR Jr, Skuta GL, Chuang AZ, Mankiewicz KA. Intermediate term safety and efficacy of transscleral cyclophotocoagulation after tube shunt failure. J Glaucoma. 2012 Feb;21(2):83-8. doi: 10.1097/IJG.0b013e31820bd1ce.</citation>
    <PMID>21336148</PMID>
  </reference>
  <reference>
    <citation>Jiménez-Román J, Gil-Carrasco F, Costa VP, Schimiti RB, Lerner F, Santana PR, Vascocellos JP, Castillejos-Chévez A, Turati M, Fabre-Miranda K. Intraocular pressure control after the implantation of a second Ahmed glaucoma valve. Int Ophthalmol. 2016 Jun;36(3):347-53. doi: 10.1007/s10792-015-0125-z. Epub 2015 Sep 3.</citation>
    <PMID>26334729</PMID>
  </reference>
  <reference>
    <citation>Semchyshyn TM, Tsai JC, Joos KM. Supplemental transscleral diode laser cyclophotocoagulation after aqueous shunt placement in refractory glaucoma. Ophthalmology. 2002 Jun;109(6):1078-84.</citation>
    <PMID>12045047</PMID>
  </reference>
  <reference>
    <citation>Smith M, Buys YM, Trope GE. Second Ahmed valve insertion in the same eye. J Glaucoma. 2009 Apr-May;18(4):336-40. doi: 10.1097/IJG.0b013e318182edfb.</citation>
    <PMID>19365202</PMID>
  </reference>
  <reference>
    <citation>Godfrey DG, Krishna R, Greenfield DS, Budenz DL, Gedde SJ, Scott IU. Implantation of second glaucoma drainage devices after failure of primary devices. Ophthalmic Surg Lasers. 2002 Jan-Feb;33(1):37-43.</citation>
    <PMID>11820661</PMID>
  </reference>
  <reference>
    <citation>Ko SJ, Hwang YH, Ahn SI, Kim HK. Surgical Outcomes of Additional Ahmed Glaucoma Valve Implantation in Refractory Glaucoma. J Glaucoma. 2016 Jun;25(6):e620-4. doi: 10.1097/IJG.0000000000000298.</citation>
    <PMID>26091182</PMID>
  </reference>
  <reference>
    <citation>Francis BA, Kawji AS, Vo NT, Dustin L, Chopra V. Endoscopic cyclophotocoagulation (ECP) in the management of uncontrolled glaucoma with prior aqueous tube shunt. J Glaucoma. 2011 Oct;20(8):523-7. doi: 10.1097/IJG.0b013e3181f46337.</citation>
    <PMID>21048513</PMID>
  </reference>
  <reference>
    <citation>Sood S, Beck AD. Cyclophotocoagulation versus sequential tube shunt as a secondary intervention following primary tube shunt failure in pediatric glaucoma. J AAPOS. 2009 Aug;13(4):379-83. doi: 10.1016/j.jaapos.2009.05.006.</citation>
    <PMID>19683190</PMID>
  </reference>
  <reference>
    <citation>Schaefer JL, Levine MA, Martorana G, Koenigsman H, Smith MF, Sherwood MB. Failed glaucoma drainage implant: long-term outcomes of a second glaucoma drainage device versus cyclophotocoagulation. Br J Ophthalmol. 2015 Dec;99(12):1718-24. doi: 10.1136/bjophthalmol-2015-306725. Epub 2015 May 29.</citation>
    <PMID>26024673</PMID>
  </reference>
  <reference>
    <citation>Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005 Sep;24(5):612-37. Review.</citation>
    <PMID>15919228</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>February 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <results_first_submitted>September 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Robert Feldman</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To the American Glaucoma Society members after completion of the study, with an institutional review board (IRB) approved protocol.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02691455/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 enrolled participants did not meet eligibility criteria and were excluded. Only one eye of each participant was eligible for enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Second Aqueous Shunt</title>
          <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
        </group>
        <group group_id="P2">
          <title>Transscleral Cyclophotocoagulation</title>
          <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Assigned Intervention</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 1 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 1 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 3 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 6 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 12 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 2 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 3 Follow up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Second Aqueous Shunt</title>
          <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
        </group>
        <group group_id="B2">
          <title>Transscleral Cyclophotocoagulation</title>
          <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="11.2"/>
                    <measurement group_id="B2" value="64.2" spread="9.8"/>
                    <measurement group_id="B3" value="63.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with autoimmune disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants for whom study eye is right eye</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glaucoma type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Primary Open Angle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Angle Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Open and Closed Glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uveitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Secondary Glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure (IOP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="8.7"/>
                    <measurement group_id="B2" value="26.2" spread="9.7"/>
                    <measurement group_id="B3" value="26.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants on ocular hypertensive medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of ocular hypertensive medications per participant</title>
          <units>medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="0.8"/>
                    <measurement group_id="B2" value="3.3" spread="1.1"/>
                    <measurement group_id="B3" value="3.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants on oral carbonic anhydrase inhibitor (CAI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best corrected visual acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). Total score ranges from -0.3 logMAR to 1.4 logMAR, with a lower number indicating the ability to read smaller letters on the Snellen chart. A lower logMAR value indicates better visual acuity; a higher logMAR value indicates lower or poorer visual acuity.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.97" spread="0.90"/>
                    <measurement group_id="B2" value="0.49" spread="0.66"/>
                    <measurement group_id="B3" value="0.74" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes That Failed Treatment</title>
        <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
        <time_frame>from time of intervention to month 6</time_frame>
        <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes That Failed Treatment</title>
          <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
          <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes That Failed Treatment</title>
        <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
        <time_frame>from month 6 to month 12</time_frame>
        <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 4 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes That Failed Treatment</title>
          <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
          <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 4 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes That Failed Treatment</title>
        <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
        <time_frame>from month 12 to year 3</time_frame>
        <population>Only one eye of each participant was eligible for enrollment. Only those who did not fail treatment in the previous time period (previous time period is reported in Outcome measure 2) were analyzed in this time period. Data for this outcome measure were not collected for 15 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes That Failed Treatment</title>
          <description>Treatment failure is defined as meeting one or more of the following 4 criteria:&#xD;
Intraocular pressure (IOP) a) &gt;18 mm Hg on maximum tolerated topical IOP-lowering medications, or b) Reduction of &lt; 20% IOP on maximum tolerated topical IOP-lowering medications from medicated preoperative IOP, or c) ≤ 5 mm Hg without IOP-lowering medications on IOP confirmation visit, 6 months after initial study intervention; or&#xD;
Reoperation for glaucoma; or&#xD;
Addition of an oral CAI for the study eye on or after the 6-Month Study Visit; or&#xD;
Loss of light perception vision (NLP).</description>
          <population>Only one eye of each participant was eligible for enrollment. Only those who did not fail treatment in the previous time period (previous time period is reported in Outcome measure 2) were analyzed in this time period. Data for this outcome measure were not collected for 15 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Vision-threatening Complications</title>
        <time_frame>from the time of intervention to year 3</time_frame>
        <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Vision-threatening Complications</title>
          <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyphema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotony persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroidal Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystoid/Diabetic Macular Edema Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Tube Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macular Hole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes Simplex Keratitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ectropion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Tube Migration Anteriorly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitreous Clogging Second glaucoma drainage device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular Lens Dislocation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phacodonesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes That Lost Two or More Lines of Vision as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The Snellen visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). Loss of lines of vision indicates worsening visual acuity.</description>
        <time_frame>from time of intervention to year 3</time_frame>
        <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes That Lost Two or More Lines of Vision as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The Snellen visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). Loss of lines of vision indicates worsening visual acuity.</description>
          <population>Only one eye of each participant was eligible for enrollment. Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The week 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, week 1</time_frame>
        <population>Data for this outcome measure was not collected 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The week 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure was not collected 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.45"/>
                    <measurement group_id="O2" value="0.14" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, month 1</time_frame>
        <population>Data for this outcome measure was not collected for 5 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 1 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure was not collected for 5 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.18"/>
                    <measurement group_id="O2" value="0.12" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, month 3</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Second Aqueous Shunt arm and 3 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure were not collected for 1 in the Second Aqueous Shunt arm and 3 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.27"/>
                    <measurement group_id="O2" value="0.08" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 6 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, month 6</time_frame>
        <population>Data for this outcome measure were not collected for 3 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 6 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure were not collected for 3 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.28"/>
                    <measurement group_id="O2" value="0.05" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 12 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, month 12</time_frame>
        <population>Data for this outcome measure were not collected for 6 in the Second Aqueous Shunt arm and 4 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The month 12 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure were not collected for 6 in the Second Aqueous Shunt arm and 4 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.34"/>
                    <measurement group_id="O2" value="0.09" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 2 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, year 2</time_frame>
        <population>Data for this outcome measure were not collected for 16 in the Second Aqueous Shunt arm and 11 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 2 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure were not collected for 16 in the Second Aqueous Shunt arm and 11 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.28"/>
                    <measurement group_id="O2" value="0.24" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
        <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
        <time_frame>baseline, year 3</time_frame>
        <population>Data for this outcome measure were not collected for 16 in the Second Aqueous Shunt arm and 15 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity as Assessed by the Snellen Chart Visual Acuity Test</title>
          <description>The visual acuity test is used to determine the smallest letters the participant can read on a standardized chart (Snellen chart). The year 3 reading minus the baseline reading is reported, with a positive number indicating a decrease in visual acuity (that is, an increase in logMAR value indicates a decrease in visual acuity).</description>
          <population>Data for this outcome measure were not collected for 16 in the Second Aqueous Shunt arm and 15 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>log MAgnification Requirement (logMAR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.36"/>
                    <measurement group_id="O2" value="0.49" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pain</title>
        <description>Number of participants who reported pain.</description>
        <time_frame>1 week</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pain</title>
          <description>Number of participants who reported pain.</description>
          <population>Data for this outcome measure were not collected for 1 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pain</title>
        <description>Number of participants who reported pain.</description>
        <time_frame>1 month</time_frame>
        <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pain</title>
          <description>Number of participants who reported pain.</description>
          <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Pain</title>
        <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
        <time_frame>1 week</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Pain</title>
          <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="1.99"/>
                    <measurement group_id="O2" value="1.44" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Pain</title>
        <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
        <time_frame>1 month</time_frame>
        <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Pain</title>
          <description>Severity of pain was assessed by the Universal Pain Assessment Tool, and the score ranges from 0 to 10, with a higher score indicating greater pain.</description>
          <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 2 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="2.23"/>
                    <measurement group_id="O2" value="1.28" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Office Visits Per Participant From Baseline to 3 Months</title>
        <time_frame>from baseline to 3 months</time_frame>
        <population>Data for this outcome measure were not collected 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Office Visits Per Participant From Baseline to 3 Months</title>
          <population>Data for this outcome measure were not collected 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>office visits per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="2.53"/>
                    <measurement group_id="O2" value="0.95" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Office Visits Per Participant Per Month After Month 3</title>
        <time_frame>from month 4 to year 3</time_frame>
        <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Office Visits Per Participant Per Month After Month 3</title>
          <population>Data for this outcome measure were not collected for 2 in the Second Aqueous Shunt arm and 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>office visits per participant per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.34"/>
                    <measurement group_id="O2" value="0.13" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute (NEI) Visual Function Questionnaire (VFQ) 25 (NEI-VFQ-25) - General Health Subscale</title>
        <description>The score on the National Eye Institute (NEI) Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute (NEI) Visual Function Questionnaire (VFQ) 25 (NEI-VFQ-25) - General Health Subscale</title>
          <description>The score on the National Eye Institute (NEI) Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="21.5"/>
                    <measurement group_id="O2" value="48.7" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Health Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Health Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="23.2"/>
                    <measurement group_id="O2" value="53.8" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" spread="23.0"/>
                    <measurement group_id="O2" value="63.2" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - General Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="21.0"/>
                    <measurement group_id="O2" value="70.8" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="28.8"/>
                    <measurement group_id="O2" value="56.9" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Mental Health Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="28.1"/>
                    <measurement group_id="O2" value="68.3" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="24.2"/>
                    <measurement group_id="O2" value="63.5" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Distance Activity Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="20.2"/>
                    <measurement group_id="O2" value="63.9" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="21.0"/>
                    <measurement group_id="O2" value="62.7" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Near Activity Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="22.7"/>
                    <measurement group_id="O2" value="59.0" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" spread="24.0"/>
                    <measurement group_id="O2" value="59.2" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Peripheral Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="23.5"/>
                    <measurement group_id="O2" value="63.5" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="22.8"/>
                    <measurement group_id="O2" value="77.6" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Color Vision Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" spread="23.2"/>
                    <measurement group_id="O2" value="76.9" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="28.6"/>
                    <measurement group_id="O2" value="70.4" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Ocular Pain Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" spread="20.0"/>
                    <measurement group_id="O2" value="81.7" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="25.0"/>
                    <measurement group_id="O2" value="55.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Driving Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="17.6"/>
                    <measurement group_id="O2" value="65.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="22.5"/>
                    <measurement group_id="O2" value="46.7" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Dependency Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="24.4"/>
                    <measurement group_id="O2" value="54.9" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="18.7"/>
                    <measurement group_id="O2" value="82.7" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Social Functioning Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="26.3"/>
                    <measurement group_id="O2" value="76.0" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>baseline</time_frame>
        <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 1 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="31.2"/>
                    <measurement group_id="O2" value="61.8" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</title>
        <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
        <time_frame>month 12</time_frame>
        <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Second Aqueous Shunt</title>
            <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
          </group>
          <group group_id="O2">
            <title>Transscleral Cyclophotocoagulation</title>
            <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life as Assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) - Role Difficulty Subscale</title>
          <description>The score on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) subscale ranges from 0 to 100, with a higher score indicating greater functioning.</description>
          <population>Data for this outcome measure were not collected for 8 in the Second Aqueous Shunt arm and 7 in the Transscleral Cyclophotocoagulation arm who received the intervention.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="25.7"/>
                    <measurement group_id="O2" value="70.2" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Second Aqueous Shunt</title>
          <description>Second Aqueous Shunt&#xD;
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.&#xD;
Baerveldt Glaucoma Implant 350-mm2 / BG101-350&#xD;
Ahmed Model FP7 Flexible Plate&#xD;
Baerveldt Glaucoma Implant 250-mm2 / BG103-250</description>
        </group>
        <group group_id="E2">
          <title>Transscleral Cyclophotocoagulation</title>
          <description>Transscleral Diode Laser Cyclophotocoagulation&#xD;
Transscleral Diode Laser Cyclophotocoagulation: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Open Globe due to trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System (CNS) Syphilis causing Pan Uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Purulent Constrictive Pericarditis, unspecified infectious etiology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Left Lung Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Left atrial myxoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain secondary to abdominal artery pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute on Chronic Combined Diastolic and Systolic Congestive Heart Failure exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heart Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-ST-Elevation Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Choroidals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Corneal Epithelial Defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decreased Visual Acuity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Development of Cystoid Macular Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Worsening of Cystoid Macular Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diabetic Macular Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Worsening Diabetic Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Filamentary Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes Simplex Virus Dendritic Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mild intraocular lens dislocation (inferior nasal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Overfiltration of Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Re-exposed tube</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ssuperior nasal tube with &lt;1 mm exposure at limbus (original tube)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Trabectome/Goniotomy of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tube Migration Anteriorly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vision loss from count fingers to light perception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vitreous clogging of second tube shunt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cataract formation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Worsening of cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>No light perception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Phacodonesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Spot on gums</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Leak/Inflammation or infection of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dislipidemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Castochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Throat Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute on Chronic Respiratory Failure with Hypoxemia and Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hypertension (secondary)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert M. Feldman, MD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 559-5239</phone>
      <email>Robert.M.Feldman@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

